Comparative Pharmacology
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus KRINTAFEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus KRINTAFEL.
CHLOROQUINE PHOSPHATE vs KRINTAFEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Adults: 200 mg orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Category C
Category C
Antimalarial
Antimalarial